As Europe works to accelerate clinical development, innovation pathways and scientific advice are becoming critical tools for aligning regulators and sponsors earlier in the process. This keynote will explore how these mechanisms are evolving across Member States and at the European level, and how earlier, more structured engagement can reduce uncertainty, improve trial design, and support faster, more efficient development.

European initiatives like FAST EU and ACT EU aim to streamline trial approval and execution, but results remain uneven across Member States. This talk will provide a candid, on-the-ground view of what is working, where bottlenecks persist, and what sponsors and regulators must change to deliver faster, more predictable study start-up in Europe.

As competition for sites, investigators, and patients intensifies, the traditional sponsor-driven model of trial execution is shifting. Increasingly, high-performing sites are selecting sponsors based on operational efficiency, burden, and partnership quality. This talk will explore how mid- and large pharma organizations are rethinking clinical operations, redefining the role of CRAs, and introducing new functions / enhanced roles to improve site engagement and execution at scale.